دورية أكاديمية
أعرض في EDS

Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial.

التفاصيل البيبلوغرافية
العنوان: Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial.
المؤلفون: Berwanger O; Research Institute - Heart Hospital (HCor), Rua Abílio Soares 250, 12th floor, CEP: 04005-000, São Paulo, SP, Brazil. Electronic address: oberwanger@hcor.com.br., Nicolau JC; Research Institute - Heart Hospital (HCor), Rua Abílio Soares 250, 12th floor, CEP: 04005-000, São Paulo, SP, Brazil., Carvalho AC; Research Institute - Heart Hospital (HCor), Rua Abílio Soares 250, 12th floor, CEP: 04005-000, São Paulo, SP, Brazil., Jiang L; Research Institute - Heart Hospital (HCor), Rua Abílio Soares 250, 12th floor, CEP: 04005-000, São Paulo, SP, Brazil., Goodman S; Research Institute - Heart Hospital (HCor), Rua Abílio Soares 250, 12th floor, CEP: 04005-000, São Paulo, SP, Brazil., Nicholls SJ; Research Institute - Heart Hospital (HCor), Rua Abílio Soares 250, 12th floor, CEP: 04005-000, São Paulo, SP, Brazil., Parkhomenko A; Research Institute - Heart Hospital (HCor), Rua Abílio Soares 250, 12th floor, CEP: 04005-000, São Paulo, SP, Brazil., Averkov O; Research Institute - Heart Hospital (HCor), Rua Abílio Soares 250, 12th floor, CEP: 04005-000, São Paulo, SP, Brazil., Tajer C; Research Institute - Heart Hospital (HCor), Rua Abílio Soares 250, 12th floor, CEP: 04005-000, São Paulo, SP, Brazil., Malaga G; Research Institute - Heart Hospital (HCor), Rua Abílio Soares 250, 12th floor, CEP: 04005-000, São Paulo, SP, Brazil., Kerr Saraiva JF; Research Institute - Heart Hospital (HCor), Rua Abílio Soares 250, 12th floor, CEP: 04005-000, São Paulo, SP, Brazil., Fonseca F; Research Institute - Heart Hospital (HCor), Rua Abílio Soares 250, 12th floor, CEP: 04005-000, São Paulo, SP, Brazil., Guimaraes HP; Research Institute - Heart Hospital (HCor), Rua Abílio Soares 250, 12th floor, CEP: 04005-000, São Paulo, SP, Brazil., de Barros E Silva PGM; Research Institute - Heart Hospital (HCor), Rua Abílio Soares 250, 12th floor, CEP: 04005-000, São Paulo, SP, Brazil., Damiani LP; Research Institute - Heart Hospital (HCor), Rua Abílio Soares 250, 12th floor, CEP: 04005-000, São Paulo, SP, Brazil., Paisani DM; Research Institute - Heart Hospital (HCor), Rua Abílio Soares 250, 12th floor, CEP: 04005-000, São Paulo, SP, Brazil., Lasagno CMR; Research Institute - Heart Hospital (HCor), Rua Abílio Soares 250, 12th floor, CEP: 04005-000, São Paulo, SP, Brazil., Candido CT; Research Institute - Heart Hospital (HCor), Rua Abílio Soares 250, 12th floor, CEP: 04005-000, São Paulo, SP, Brazil., Valeis N; Research Institute - Heart Hospital (HCor), Rua Abílio Soares 250, 12th floor, CEP: 04005-000, São Paulo, SP, Brazil., Moia DDF; Research Institute - Heart Hospital (HCor), Rua Abílio Soares 250, 12th floor, CEP: 04005-000, São Paulo, SP, Brazil., Piegas LS; Research Institute - Heart Hospital (HCor), Rua Abílio Soares 250, 12th floor, CEP: 04005-000, São Paulo, SP, Brazil., Granger CB; Research Institute - Heart Hospital (HCor), Rua Abílio Soares 250, 12th floor, CEP: 04005-000, São Paulo, SP, Brazil., White H; Research Institute - Heart Hospital (HCor), Rua Abílio Soares 250, 12th floor, CEP: 04005-000, São Paulo, SP, Brazil., Lopes RD; Research Institute - Heart Hospital (HCor), Rua Abílio Soares 250, 12th floor, CEP: 04005-000, São Paulo, SP, Brazil.
المصدر: American heart journal [Am Heart J] 2018 Aug; Vol. 202, pp. 89-96. Date of Electronic Publication: 2018 Mar 03.
نوع المنشور: Clinical Trial, Phase III; Comparative Study; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Mosby Country of Publication: United States NLM ID: 0370465 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6744 (Electronic) Linking ISSN: 00028703 NLM ISO Abbreviation: Am Heart J Subsets: MEDLINE
أسماء مطبوعة: Original Publication: St. Louis, MO : Mosby
مواضيع طبية MeSH: Clopidogrel/*therapeutic use , Fibrinolytic Agents/*therapeutic use , Hemorrhage/*chemically induced , Purinergic P2Y Receptor Antagonists/*therapeutic use , Ticagrelor/*therapeutic use, Adult ; Aged ; Anticoagulants/therapeutic use ; Clopidogrel/adverse effects ; Drug Therapy, Combination ; Female ; Humans ; Intention to Treat Analysis ; Male ; Middle Aged ; Prospective Studies ; Purinergic P2Y Receptor Antagonists/adverse effects ; Research Design ; ST Elevation Myocardial Infarction ; Single-Blind Method ; Ticagrelor/adverse effects
مستخلص: Background: The safety and efficacy of ticagrelor in patients with ST-elevation myocardial infarction (STEMI) treated with fibrinolytic therapy remain uncertain.
Objectives: The primary objective of the TicagRElor in pAtients with ST elevation myocardial infarction treated with Thrombolysis (TREAT) trial is to evaluate the short-term safety of ticagrelor when compared with clopidogrel in STEMI patients treated with fibrinolytic therapy. Key secondary objectives are to assess the safety and efficacy of ticagrelor compared with clopidogrel at 12-months.
Design: The TREAT trial is a multicenter, randomized, phase III, Prospective randomized open blinded end-point (PROBE) study that enrolled 3,799 patients in 152 sites from 10 countries. Following administration of fibrinolytic therapy patients were randomized to a loading dose of ticagrelor 180 mg or clopidogrel 300 mg followed by a maintenance dose of ticagrelor 90 mg twice daily or clopidogrel 75 mg/day for 12-months. The primary outcome is the rate of TIMI major bleeding at 30-days and will be assessed for non-inferiority using an intention-to-treat analysis. Co-treatments include aspirin and anticoagulants. Other evidence based therapies are also recommended. Secondary efficacy outcome include a composite of death from vascular causes, myocardial infarction, stroke, severe recurrent ischemia, transient ischemic attack or other arterial thrombotic event. All-cause mortality as well as individual components of the combined efficacy endpoint will also be ascertained.
Summary: TREAT is an international randomized controlled trial comparing ticagrelor with clopidogrel in STEMI patients treated with fibrinolytic therapy. The results of this trial will inform clinical practice and international guidelines.
(Copyright © 2018 Elsevier Inc. All rights reserved.)
المشرفين على المادة: 0 (Anticoagulants)
0 (Fibrinolytic Agents)
0 (Purinergic P2Y Receptor Antagonists)
A74586SNO7 (Clopidogrel)
GLH0314RVC (Ticagrelor)
تواريخ الأحداث: Date Created: 20180617 Date Completed: 20190503 Latest Revision: 20190503
رمز التحديث: 20240829
DOI: 10.1016/j.ahj.2018.02.017
PMID: 29908420
قاعدة البيانات: MEDLINE
الوصف
تدمد:1097-6744
DOI:10.1016/j.ahj.2018.02.017